Effects of COX-2 inhibitors on aortic prostacyclin production in cholesterol-fed rabbits

Atherosclerosis

Volumn 157, Issue 2, 2001, Pages 393-402

  Wong, Elizabeth ^a   Huang, JingQi ^a   Tagari, Philip ^a   Riendeau, Denis ^a  

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

Author keywords

Atherosclerosis; Cyclooxygenase; NSAID; Prostacyclin; Prostaglandin

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; ANTIINFLAMMATORY AGENT; ARACHIDONIC ACID; CELECOXIB; CHOLESTEROL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DYFLOS; FURANONE DERIVATIVE; INDOMETACIN; PROSTACYCLIN SYNTHASE; PROSTAGLANDIN E2; PROSTANOID; ROFECOXIB; THROMBOCYTE SLOWING FACTOR; VASODILATOR AGENT;

ACUTE DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL DIET; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; FATTY ACID BLOOD LEVEL; FATTY ACID SYNTHESIS; INHIBITION KINETICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE AGGREGATION;

ANIMALS; AORTA; BLOTTING, WESTERN; BODY WEIGHT; CHOLESTEROL; CHOLESTEROL, DIETARY; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; EICOSANOIDS; EPOPROSTENOL; IMMUNOHISTOCHEMISTRY; ISOENZYMES; MALE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; RABBITS; REFERENCE VALUES; TRIGLYCERIDES;

EID: 0034900837     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(00)00756-5     Document Type: Article

References (51)

1. Cyclooxygenase in biology and disease
2. Anti-inflammatory drugs and their mechanism of action
3. Cox-2-selective inhibitors: The new super aspirins
4. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
5. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids
6. Upregulation of prostacyclin synthesis-related gene expression by shear stress in vascular endothelial cells
7. Rate of vasoconstrictor prostanoids released by endothelial cells depends on cyclooxygenase-2 expression and prostaglandin I synthase activity
8. Cyclooxygenase-2 as a therapeutic target
9. Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells
10. Induction of cyclooxygenase-2 in rat vascular smooth muscle cells in vitro and in vivo
11. Atherosclerosis - An inflammatory disease
12. Inflammation of the atherosclerotic cap and shoulder of the plaque is a common and locally observed feature in unruptured plaques of femoral and coronary arteries
13. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: Cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress
14. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase
15. Triphasic response of prostacyclin production in rabbit thoracic aorta in early atherosclerosis
16. 2 by cholesterol-fed rabbits
17. 2 biosynthesis in atherosclerosis
18. 2 formation in atherosclerotic human carotid artery
19. Low density lipoprotein is protected from oxidation and the progression of atherosclerosis is slowed in cholesterol-fed rabbits by the antioxidant N,N′-diphenyl-phenylenediamine
20. Rofecoxib [Vioxx™, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: A potent, highly selective and orally active cyclooxygenase-2 inhibitor: Pharmacological and biochemical profiles
21. SAR in the alkoxy lactone series: The discovery of DFP, a potent and orally active COX-2 inhibitor
22. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3- (trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, celecoxib)
23. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis, Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde- lysine in serum
24. Characterization of autocrine inducible prostaglandin H synthase-2 (PGHS-2) in human osteosarcoma cells
25. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer
26. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts
27. Immunocytochemical analysis of cellular components in atherosclerotic lesions, Use of monoclonal antibodies with the Watanabe and fat-fed rabbit
28. Co-localization of the cysteine protease caspase-3 with apoptotic myocytes after in vivo myocardial ischemia and reperfusion in the rat
29. Diet-induced atherosclerosis in rabbits alters vascular prostacyclin release
30. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association
31. Fatty streak initiation in Watanabe Heritable Hyperlipemic and comparably hypercholesterolemic fat-fed rabbits
32. Fatty streak expansion and maturation in Watanabe Heritable Hyperlipemic and comparably hypercholesterolemic fat-fed rabbits
33. Release of prostaglandins and monohydroxy and trihydroxy metabolites of linoleic and arachidonic acids by adult and fetal aortae and ductus arteriosus
34. Prostaglandin and HETE synthesis by aortae and hearts of normal and atherosclerotic rabbits
35. 2 isoforms in human normal and atherosclerotic arterial wall
36. Induction of 15-lipoxygenase mRNA and protein in early atherosclerotic lesions
37. The role of 15-lipoxygenase in atherogenesis: Pro- and antiatherogenic actions
38. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions
39. Selective cyclo-oxygenase-2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence
40. Localization and distribution of cyclooxygenase-2 in brain tissue by immunohistochemistry
41. Colocalization of prostacyclin synthase with prostaglandin H synthase-1 (PGHS-1) but not phorbol ester-induced PGHS-2 in cultured endothelial cells
42. Glucocorticoids downregulate cyclooxygenase-1 gene expression and prostacyclin synthesis in fetal pulmonary artery endothelium
43. Estrogen upregulates cyclooxygenase-1 gene expression in ovine fetal pulmonary artery endothelium
44. Chronic inhibition of NO synthase enhances the production of prostacyclin in coronary arteries through upregulation of the cyclooxygenase type 1 isoform
45. Transcriptional profile of mechanically induced genes in human vascular smooth muscle cells
46. Inducible cyclooxygenase and nitric oxide synthase
47. Metabolic disposition of prostacyclin in humans
48. Measurement of renal and non-renal eicosanoid synthesis
49. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages
50. Arachidonic acid is preferentially metabolized by cyclooxygenase-2 to prostacyclin and prostaglandin E2
51. HDL-induced prostacyclin release in smooth muscle cells is dependent on cyclooxygenase-2 (Cox-2)